Get the full picture
Sign in to uncover key details.
Show More
Alterome
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
13480 Evening Creek Dr N Ste 450, San Di...Website
www.alterome.comRevenue
<$5 MillionIndustry
About Alterome
Alterome Therapeutics is a clinical-stage precision oncology company focused on developing first-in-class, alteration-specific therapies for AKT E17K- and KRAS-driven cancers. The company aims to tackle challenging cancer targets that have been difficult for conventional drug development, particularly in non-small cell lung, pancreatic, colorectal, endometrial, and breast cancers. With a mission-driven team that combines expertise in biology, chemistry, and advanced drug design, Alterome has successfully advanced two unique cancer therapies into clinical trials. Their commitment to transforming the lives of cancer patients is reflected in their innovative approach and robust pipeline.Explore more
Alterome Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Alterome
Compare insights from companies similar to Alterome, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Alterome Tech Stack
A closer look at the technologies used by Alterome
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Alterome
Sign Up For FreeTo access detailed company insights
Alterome Therapeutics is a clinical-stage precision oncology company focused on developing first-in-class, alteration-specific therapies for AKT E17K- and KRAS-driven cancers. The company aims to tackle challenging cancer targets that have been difficult for conventional drug development, particularly in non-small cell lung, pancreatic, colorectal,... Read More
